DB16149InvestigationalProtein Based Therapies
Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker. It is under investigation... It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).
- Mechanism
- Curator reviewed
Pharmacologically active on Interleukin-2 receptor
- Also known as
- Fc il-2 mutein fusion protein (amg-592) · Immunoglobulin g1 (fc domain-containing fragment) fusion protein with peptide (synthetic linker) fusion protein with interleukin 2 (synthetic human mutein), dimer
- Code names
- AMG-592
Resolves to
Compound
What you can answer from here — as of July 08, 2026
Which companies are running trials of Efavaleukin alfa, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account